About the Belfer Institute

The Belfer Institute for Applied Cancer Science is a fully integrated, collaborative cancer research center dedicated to translating today’s most innovative oncology research into tomorrow’s most promising cancer treatments. This highly focused, goal-oriented organization represents a new academic construct that embeds an industrial approach within a premier academic setting. The Institute’s excellence in leading edge early-stage biology enables its scientists to define the best targets and the optimal clinical path for targeted cancer therapies. The Belfer Institute’s strategic collaborations with leading pharmaceutical companies are driving the development of a next generation of cancer therapies. The Belfer Institute is part of the Dana-Farber Cancer Institute and is affiliated with Harvard Medical School.

In the News

Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.

read more >

Oral presentation, Serial monitoring of EGFR mutations in plasma NSCLC patients by ddPCR, at the 2014 AACR General Meeting in San Diego by Cloud Paweletz PhD, Head of Translational Research Lab.

read more >

Findings from the Translational Research Lab within the Belfer Institute demonstrate that circulating DNA from non-invasive plasma samples is a promising biomarker to monitor response and predict resistance in the clinic.

read more >

Belfer scientists collaborate with W. Kaelin MD , to demonstrate that the Ikaros family of transcription factors are key downstream mediators of the efficacy of thalidomide-like drugs.

read more >

Pioneering study from the lab of Kwok Wong MD PhD, demonstrating that specific tumor mutations can drive immune escape, which has significant implications for the clinical development of immunomodulatory agents.

read more >